HK inno.N’s Obesity Drug Candidate Outperforms Wegovy in Head-to-Head Phase 2 Trial
HK inno.N announced on June 9 that its obesity drug candidate, ecnoglutide, demonstrated superior weight-loss efficacy compared to semaglutide—the...
Search results for "Phase 3 trial"
Abl Bio Confirms Positive Effects of Cancer Drug 'ABL111' in Phase 1b Clinical Trial
Abl Bio announced on the 7th that it has confirmed positive anti-cancer efficacy in the dose expansion cohort of the Phase 1b clinical trial for its...
Combination Therapy: Laennec Achieves Pain Relief with One-Fifth the Steroid Dose in Preclinical Study
An animal study has revealed that combining GC Green Cross Wellbeing’s human placental hydrolysate treatment, Laennec...
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are...
Zinc and Selenium Deficiencies Linked to Heightened Inflammation in Critically Ill Patients
For families with loved ones in an intensive care unit , lab reports often feature unfamiliar line items alongside...
550 Days in Limbo: Groups Demand 100-Day Fast-Track Insurance Coverage for Breakthrough PAH Drug Winrevair
With national health insurance coverage for the new pulmonary arterial hypertension treatment Winrevair (active...
Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27
Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's...
Hanmi Control Dispute Reignites as Court Freezes 10 Billion Won in Lim Ju-hyun’s Shares
The "four-party alliance" formed to stabilize management control at Hanmi Pharmaceutical Group has descended into open...
HK inno.N's K-CAB Secures Sixth Indication to Prevent Ulcers from Long-Term NSAID Use
HK inno.N’s gastroesophageal reflux disease drug K-CAB has expanded its approved uses to include the prevention of...
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C...